
|Podcasts|August 21, 2019
Mastering New Advances in Hematologic Malignancies in Milwaukee
Author(s)Onclive Team
We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from the Medical College of Wisconsin.
Advertisement
We recently traveled to Milwaukee, Wisconsin for a State of the Science Summit™ on Hematologic Malignancies. We met with experts from the Medical College of Wisconsin to gather updates in acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and myeloproliferative neoplasms. Additionally, we heard the latest news surrounding chimeric antigen receptor T-cell therapy and a slew of ongoing, and potentially practice-changing, trials in the hematologic cancer space.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































